Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04153136 · ClinicalTrials.gov registry record · Phase 2
The ENCHANTMENT HIV Study
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT04153136: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04153136 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04153136, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.
Interventions
- DRUG Placebo oral tablet
- DRUG Sacubitril-Valsartan 49-51Mg Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04153136
The ClinicalTrials.gov registry entry for NCT04153136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04153136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04153136 about?
NCT04153136 is a clinical study titled "The ENCHANTMENT HIV Study". Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes i...
What is the current status of trial NCT04153136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2020-09-11. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT04153136?
The interventions under investigation include: Placebo oral tablet (DRUG), Sacubitril-Valsartan 49-51Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04153136?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.